Cost-utility analysis of molnupiravir plus usual care versus usual care alone as early treatment for community-based adults with COVID-19 and increased risk of adverse outcomes in the UK PANORAMIC trial

Cost-utility analysis of molnupiravir plus usual care versus usual care alone as early treatment for community-based adults with COVID-19 and increased risk of adverse outcomes in the UK PANORAMIC trial

<p><strong>Background </p></strong>The cost-effectiveness of molnupiravir, an oral antiviral for early treatment of SARS-CoV-2, has not been established in vaccinated populations. <p><strong> Aim </p></strong>To evaluate the cost-effectiveness of molnu...

وصف كامل

التفاصيل البيبلوغرافية
المؤلفون الرئيسيون: Png, ME, Harris, V, Grabey, J, Hart, ND, Jani, BD, Butler, D, Carson-Stevens, A, Coates, M, Cureton, L, Dobson, M, Dorward, J, Evans, P, Francis, N, Gbinigie, OA, Hayward, G, Holmes, J, Hood, K, Khoo, S, Ahmed, H, Lown, M, McKenna, M, Mort, S, Nguyen-Van-Tam, J, Rahman, N, Richards, DB, Thomas, N, van Hecke, O, Hobbs, FR, Little, P, Yu, L-M, Butler, CC, Petrou, S
مؤلفون آخرون: PANORAMIC Trial Collaborators
التنسيق: Journal article
اللغة:English
منشور في: Royal College of General Practitioners 2024

مواد مشابهة